Loading...

CYTM

GDTC

CYTOMED THERAPEUTICS LTD

(GDTC)

2025 6-K

Show Summary

Summary

Company Expansion

ATM Offering Program

Clinical Trial Update

Share Issuance Approval

Annual Meeting Results

Annual Meeting Notice

Financial Results Update

Collaboration Agreement

Leadership Changes

First Patient Dosed

Clinical Trial Funding

Asset Acquisition

Financial Report Update

Board Restructure

Board Resignation

Annual Shareholders Meeting

Proxy Statement Update

Annual Meeting Notice

Shareholder Cell Banking

Research Partnership

External Links:

On July 1, 2025, CytoMed Therapeutics Ltd issued a total of 63,250 ordinary shares to company executives as compensation, with a six-month restriction period; this follows approval by the board on May 1, 2025.

AI Assistant

CYTOMED THERAPEUTICS LTD

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.